Dosage Forms – Page 4

Ionis Advances to Phase 3 Trial for Angelman Syndrome Treatment ION582

9 months ago talkbio0Tagged Angelman Syndrome, Antisense, Biogen, Dosage Forms, ION582, Ionis Pharmaceuticals, neurological conditions, Oligonucleotides, Phase 3 trial, Ultragenyx

Ionis Pharmaceuticals, Angelman syndrome, ION582, Phase 3 trial, antisense oligonucleotides, neurological conditions, rare diseases, Biogen, Ultragenyx Pharmaceutical

How the world’s biggest pharma and biotech companies paid their typical worker in 2023

10 months ago talkbio0Tagged 2023, Dosage Forms, Industry, Worker, world 's

Dosage Forms, Industry, world ‘s, Worker, 2023

Ono Pharmaceutical Strengthens Oncology Portfolio with Acquisition of Deciphera Pharmaceuticals for $2.4 Billion

12 months ago talkbio0Tagged Acquisition (action), cancer treatments, Clinical Development, Collaboration, Deciphera, Dosage Forms, expansion, Generalized, Market, Oncology Pipeline, strategic

Ono Pharmaceutical, Deciphera Pharmaceuticals, oncology pipeline, acquisition, $2.4 billion, cancer treatments, kinase inhibitors, strategic expansion, global market, clinical development, collaboration.

Endo’s Par Pharmaceutical Recalls Blood Pressure Medication Due to Potential Contamination

12 months ago talkbio0Tagged adulteration, blood pressure medication, Dosage Forms, Endometriosis, Expiration, function, hydrochlorothiazide, Mental Recall, mg/12.5, Tablet Dosage Form

Endo, Par Pharmaceutical, recall, blood pressure medication, contamination, quinapril HCl/ hydrochlorothiazide tablets, USP 20 mg/12.5 mg, lot number 0KG190092, expiration date 03/2022

Incyte Invests in Mast Cell Inhibitors with $750M Escient Acquisition

1 year ago talkbio0Tagged Acquisition (action), Dosage Forms, Drug Development, Escient, Fibrosis, Incyte, Inflammatory disorder, mast cell inhibitors

Incyte, Escient, mast cell inhibitors, acquisition, pharmaceutical, drug development, inflammatory diseases, cancer, fibrosis, $750 million